MannKind Corporation (MNKD) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals. While there is positive growth in FUROSCIX sales and strategic product launches, declines in Tyvaso DPI revenues and GAAP net losses are concerning. The Q&A reveals positive sentiment towards FUROSCIX and Afrezza growth but lacks clarity on some strategic initiatives. The market cap suggests moderate volatility, and the combination of optimistic guidance with some financial setbacks results in a neutral prediction for stock movement.
Key Financial Performance
Quarterly Revenues $90 million, a 15% increase year-over-year. The increase includes the addition of FUROSCIX. However, Q1 was challenging due to structural issues like annual deductible resets, transitional disruptions from field team reorganization, and inventory adjustments for the upcoming launch of the auto-injector.
FUROSCIX Net Sales $15.5 million for Q1 2026. Doses dispensed grew 64% year-over-year, and IDN business grew 97% year-over-year. The growth reflects strong demand metrics, including a record number of writers and 75% repeat writers.
Afrezza Global Sales $15.3 million for Q1 2026, up 3% year-over-year. Growth slowed due to reallocation of marketing resources towards pediatric Afrezza launch and FUROSCIX nephrology opportunity.
Tyvaso DPI-Related Revenues $23.5 million for Q1 2026, compared to $29.4 million in the prior year. The decrease is attributed to production scheduling fluctuations at the Danbury facility. However, annual minimum quantities in the supply agreement provide revenue stability.
Royalties $32.7 million for Q1 2026, reflecting a 9% year-over-year growth. Royalties support key capital priorities, including debt reduction and pipeline programs.
GAAP Net Loss $16.6 million or $0.05 per share for Q1 2026, compared to GAAP net income of $13.2 million in Q1 2025. The loss is due to increased commercial investment for upcoming launches and costs associated with the SC Pharma acquisition.
Non-GAAP Net Loss $6.9 million or $0.02 per share for Q1 2026, compared to non-GAAP net income of $21.6 million in Q1 2025. The change reflects planned investments in commercial infrastructure and pipeline development.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
MannKind 1501 (ralinepag DPI): Unveiled as ralinepag DPI, with potential to earn $35 million in development milestones and 10% royalty on net sales. Targets pulmonary arterial hypertension and other lung diseases, impacting over 250,000 patients.
Afrezza Pediatrics: FDA approved updated label for pediatric use. Launch readiness completed ahead of May 29 PDUFA date. Targets 360,000 children and adolescents with type 1 diabetes in the U.S.
FUROSCIX ReadyFlow Auto-Injector: Pending FDA approval (July 26). Reduces administration time from hours to seconds, improving patient convenience and adoption. Expected to significantly reduce cost of goods.
Afrezza Pediatric Market: Targets 360,000 children and adolescents with type 1 diabetes in the U.S., with potential to expand to broader populations.
FUROSCIX Market Expansion: Addresses 700,000 fluid overload events outside hospitals. ReadyFlow auto-injector expected to unlock additional intervention points and expand prescriber adoption.
Revenue Growth: Q1 2026 revenues reached $90 million, a 15% increase year-over-year. FUROSCIX doses dispensed grew 64% year-over-year.
Operational Adjustments: Reorganized field teams and reallocated marketing resources to support upcoming product launches, causing temporary disruptions in Q1.
Manufacturing Expansion: Scaling Danbury, Connecticut facility to support FUROSCIX ReadyFlow growth and other pipeline products.
Diversification Strategy: Evolved from a single-product company to a diversified cardiometabolic and orphan lung company with multiple FDA-approved products.
United Therapeutics Partnership: Expanded collaboration with United Therapeutics, including ralinepag DPI and Tyvaso DPI, providing stable revenue and growth potential.
Pipeline Development: Advancing MannKind 201 (nintedanib DPI) into Phase II trials, targeting improved tolerability and efficacy for IPF patients.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Challenges: Q1 revenue was lighter than expected due to structural issues like annual deductible resets, transitional disruptions from field team reorganization, and inventory adjustments for upcoming product launches.
Product Launch Risks: Potential delays or challenges in the FDA approval process for Afrezza pediatrics and FUROSCIX ReadyFlow auto-injector could impact revenue and growth projections.
Market Adoption Challenges: The current FUROSCIX on-body infuser has been a barrier to adoption in certain patient segments, and the success of the ReadyFlow auto-injector depends on overcoming these barriers.
Operational Disruptions: Reorganization of field teams and reallocation of marketing resources caused customer disruptions and slowed growth for Afrezza adult sales.
Regulatory and Compliance Risks: Dependence on FDA approvals for new products and label updates introduces regulatory risks that could delay or hinder product launches.
Supply Chain and Manufacturing Risks: Scaling the Danbury facility and transitioning inventory levels for new product launches pose risks of supply chain disruptions.
Economic and Financial Risks: Increased SG&A expenses and R&D investments for upcoming launches and pipeline development could strain financial resources if revenue targets are not met.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for FUROSCIX: The company reaffirms its 2026 FUROSCIX revenue target of $110 million to $120 million.
Afrezza Pediatric Launch: If approved, Afrezza will be the first needle-free mealtime insulin option for children and adolescents. The pediatric market represents a significant growth opportunity, with a potential peak share of 23%-37%, translating to approximately $150 million in net revenue for every 10% share.
FUROSCIX ReadyFlow Auto-Injector Launch: The ReadyFlow auto-injector, pending FDA approval on July 26, 2026, is expected to reduce administration time from hours to seconds, improve patient convenience, and expand adoption. Approximately 85% of existing FUROSCIX patients are expected to convert to the ReadyFlow auto-injector, and 65% of healthcare providers anticipate expanding their use.
Nintedanib DPI Program: The company plans to report Phase IB top-line data in Q3 2026 and has initiated enrollment for a global Phase II trial. The program targets improved tolerability and efficacy for IPF patients.
Ralinepag DPI Development: The company expects to earn $15 million in development milestones over the next 12 months as part of its collaboration with United Therapeutics.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the purpose of running a QID arm in the Phase II trial?
A:The purpose is to explore whether using 4 milligrams twice a day or 2 milligrams 4 times a day yields comparable outcomes. If one is better, it will be prioritized.
Q:What trends were observed with FUROSCIX in the quarter?
A:Two competitors launched last October with minimal activity (40-50 scripts). Anecdotal reports indicate some patients switched back to FUROSCIX due to better efficacy. Prescriptions picked up in March after disruptions in January and February. The auto-injector is expected to drive faster growth in Q3 and Q4.
Q:What is the progress on the ralinepag DPI development?
A:The company has a lead powder ready for human and animal trials. Confidence is based on UT's modeling and progress. Updates are expected throughout the year and next year.
Q:What is the anticipated adoption curve for Afrezza DTI post-approval?
A:The approval is expected before the American Diabetes Association event, which will help spread awareness. A staged rollout is planned, focusing on top prescribers and updating the reimbursement hub. Initial impact may be seen in Q2, with more significant adoption in Q3 and Q4.
Q:What is the sales forecast for FUROSCIX this year, and how does the auto-injector factor in?
A:The sales forecast is $110-$120 million, primarily driven by the on-body infusion. The auto-injector is expected to accelerate growth but is not the main driver of the forecast.
Q:What is the positioning of prostacyclins versus Treprostinil-based drugs for PAH?
A:Tyvaso DPI and nebulizer are expected to drive growth in the next 2-3 years. Ralinepag DPI may be used earlier due to convenience, with Tyvaso DPI being used second or third line. Ralinepag DPI is expected to dominate in IPF development.
Q:What are the contracting and success metrics for Afrezza Pediatrics?
A:No new SKUs are needed for contracting. Efforts are focused on Medicaid and PBM access. Success metrics include prescriber adoption, institutional trials, and patient referrals. Access programs will minimize payer friction.
Q:What is the progress and focus of the 201 program?
A:Phase Ia showed no major concerns with cough, GI side effects, or FEV1/FVC. Phase Ib in IPF patients showed good tolerability. Phase II will focus on ex-U.S. enrollment, with potential U.S. sites pending FDA negotiations.
Q:What is the timeline and process for integrating FUROSCIX into discharge protocols?
A:Integration takes 6-15 months and involves patient navigators, quality teams, pharmacists, and contracts. Cleveland Clinic and Kaiser are examples of institutions adopting protocols. Trial results on early discharge are expected later this year.
Q:What is the expected transition from infusion to auto-injector for FUROSCIX?
A:The transition is expected to be quick due to the acute use nature of the drug. The auto-injector simplifies use and distribution, especially for hospital discharges. The on-body infuser will still be available for some users.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the pharmacokinetics of ralinepag DPI, deferring to UT's modeling and stating that the real answer will only be known after human trials. Additionally, the positioning of prostacyclins versus Treprostinil-based drugs for PAH was described in general terms without specific data or clarity on commercial opportunities.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
American
Association
FUROSCIX ReadyFlow
Number
PDUFA
Phase IB
Phase II
ReadyFlow auto
access
account manager
acquisition
addition
adoption
afternoon
auto injector
balance
base
body infuser
brand
child adolescent
cost
disease
enrollment Phase
integration
intervention
mealtime
milestone
nintedanib DPI
note
parallel
program potential
ralinepag DPI
start
term catalyst
type diabetes
writer
MNKD Transcript
MannKind Corporation (MNKD) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call presents mixed signals. While there is positive growth in FUROSCIX sales and strategic product launches, declines in Tyvaso DPI revenues and GAAP net losses are concerning. The Q&A reveals positive sentiment towards FUROSCIX and Afrezza growth but lacks clarity on some strategic initiatives. The market cap suggests moderate volatility, and the combination of optimistic guidance with some financial setbacks results in a neutral prediction for stock movement.
MannKind Corporation (MNKD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
MannKind Corporation (MNKD) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary highlights strong financial performance, with significant revenue growth driven by Afrezza and FUROSCIX. Product development is advancing, with promising pipeline updates and strategic initiatives. Market strategy and shareholder return plans are not explicitly detailed but implied through growth projections. The Q&A session reveals optimism for future revenue growth, particularly with the pediatric segment and FUROSCIX auto-injector launch. Despite some management vagueness, the overall sentiment is positive, with potential catalysts for stock price appreciation. Considering the small-cap nature, a positive stock price movement (2% to 8%) is expected.
MannKind Corporation (MNKD) Q3 2025 Earnings Call Transcript
Positive11-5
The earnings call highlights strong financial metrics, optimistic guidance, and strategic growth initiatives. The company expects significant growth in Afrezza sales and FUROSCIX, supported by investments in sales force expansion and new product developments. The strategic financing with Blackstone provides a substantial non-dilutive funding boost. Market opportunities, especially in the NTM market, are promising, and the company is confident in its pricing model. Despite some unclear management responses, the overall sentiment is positive, with potential catalysts like the Afrezza label update and ReadyFlow injector expansion.
MNKD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
